Verrian is focused on validating promising preclinical evidence for the treatment of addition through natural psychedelics. In conjunction with its strategic partners, the company's medical team studies new formulations to rapidly develop and commercialize new therapies that incorporate custom genetics for maximum consistency.
The company's existing product lines include PsiGen, a psilocybin extract from organically-cultivated mushrooms with metabolism-enhancing herbs, and PsiGen+, similar product with enhanced features. Both of these products are designed for individuals that are micro-dosing with a tri-weekly minimum administration.
The company owns and operates a 110,000 sq. ft. manufacturing facility in Radebeul, Germany, with re-inspection planned in 2020 to confirm EU-GMP & ISO 14001 standards.
Global Operations Director